Related Experiment Video

Updated: Jul 1, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Exploitation of protein kinase C: a useful target for cancer therapy

Ashhar S Ali1, Shadan Ali, Bassel F El-Rayes

  • 1Department of Pathology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA.

Cancer Treatment Reviews
|September 10, 2008
PubMed

Insights

Protein kinase C (PKC) isozymes are crucial in cell functions and cancer development. Targeting PKC offers a promising strategy for cancer prevention and therapy, despite current challenges.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Protein kinase C (PKC) comprises at least 12 serine/threonine kinase isozymes involved in critical cellular processes.
  • PKC isozymes regulate key signaling pathways such as PI3-K/Akt, MAPK, and GSK-3beta.
  • Dysregulation of PKC isozymes is frequently observed in various cancers, including prostate, breast, colon, pancreatic, liver, and kidney.

Purpose of the Study:

  • To review the role of Protein Kinase C (PKC) isozymes in cell biology and cancer.
  • To highlight the significance of PKC isozymes in tumor development and progression.
  • To discuss the therapeutic potential and challenges of targeting PKC in cancer treatment.

Main Methods:

  • Literature review of scientific articles on Protein Kinase C (PKC).
  • Analysis of PKC isozyme involvement in cell signaling and cancer biology.
  • Examination of current clinical trials and challenges in PKC inhibitor development.

Main Results:

  • PKC isozymes play diverse roles in cell proliferation, differentiation, angiogenesis, and apoptosis.
  • PKC activation is linked to tyrosine-kinase and G-protein-coupled receptors.
  • PKC isozymes are implicated in the pathogenesis of multiple human cancers.

Conclusions:

  • Protein Kinase C (PKC) isozymes are vital regulators of cellular functions and are implicated in cancer.
  • Targeting PKC isozymes presents a promising avenue for cancer prevention and therapy.
  • Further research is needed to overcome challenges in developing effective PKC-targeted cancer treatments.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: